申请人:Novartis International Pharmaceutical Ltd.
公开号:US08129395B2
公开(公告)日:2012-03-06
4,5-disubstituted-2-arypyrimidines of Formula I and Formula II are provided:
wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.
提供了式I和式II的4,5-二取代-2-芳基嘧啶化合物,其中R1、R2、R3、R8、R9、A和Ar的定义详见说明书。这些化合物是C5a受体的配体。式I和II的优选化合物具有高亲和力结合C5a受体,并在C5a受体上表现为中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的药物组合物,以及使用这些化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外,本发明提供了标记的4,5-二取代-2-芳基嘧啶化合物,可用作定位C5a受体的探针。